olivLaw · US equity research
Rapid Micro Biosystems, Inc. RPID
Laboratory Analytical Instruments · SIC 3826 · Vertical: Laboratory Analytical Instruments (SIC 3826)
Rapid Micro Biosystems develops the Growth Direct platform, an automated system for microbial quality control in pharmaceutical manufacturing, used especially for biologics, cell and gene therapies. The company is pushing toward full automation of MQC testing, and its distribution agreement with MilliporeSigma and growing recurring revenue could support a steadier trajectory if system placements keep pace; 2025 revenue was 33.6 million USD, with a net loss of 47.1 million USD.
At the close of 04 Nov 2026, Rapid Micro Biosystems, Inc. (RPID) stock was 0.68 USD (−1.59% on the day), with beta 1.69, 52-week range 0.68–4.68 USD. Latest reported quarter (Q2 2026): revenue of 8.1 m USD (+10.9% YoY), net income of -12.9 m USD, diluted EPS -0.27 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 22.7
- oversold (≤ 30)
- Bollinger (20, 2)
- 0.67 – 0.91
- in the lower half of the band · %B 0.03 · band width 30.3%
- SMA 50 / 200
- 1.07 / 2.24
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.10 / -0.11
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −30.2% | −1.1% | −29.1 pp | — |
| 3 months | −67.7% | −0.5% | −67.3 pp | — |
| 6 months | −73.1% | +4.4% | −77.5 pp | — |
| Year to date | −76.5% | +12.3% | −88.8 pp | — |
| 1 year | −74.8% | +13.5% | −88.3 pp | +15.7% |
| 3 years | −37.5% | +76.4% | −113.9 pp | +1.8% |
| 5 years | −96.9% | +63.7% | −160.5 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.6 m | 8.2 m | 7.2 m | 7.3 m | 7.8 m | 11.3 m | 8.0 m | 8.1 m |
| Cost of revenue | — | — | 6.8 m | 7.0 m | — | — | 7.6 m | 6.8 m |
| Gross profit | — | — | 404.0 k | 275.0 k | — | — | 371.0 k | 1.2 m |
| Research & development | 3.6 m | 3.4 m | 3.6 m | 3.2 m | 3.5 m | 3.2 m | 3.4 m | 3.3 m |
| Operating income | -12.0 m | -10.2 m | -11.7 m | -12.1 m | -11.4 m | -12.2 m | -13.9 m | -12.3 m |
| Depreciation & amortisation | 859.0 k ≈ | 869.0 k | 847.0 k | 811.0 k ≈ | 804.0 k ≈ | 790.0 k | 706.0 k | 674.0 k ≈ |
| Interest expense | 11.0 k | 12.0 k | 12.0 k | 12.0 k | 393.0 k | 673.0 k | 639.0 k | 646.0 k |
| Income tax | 13.0 k | -9.0 k | 7.0 k | 11.0 k | 8.0 k | 14.0 k | 8.0 k | 45.0 k |
| Net income | -11.3 m | -9.7 m | -11.3 m | -11.9 m | -11.5 m | -12.5 m | -14.3 m | -12.9 m |
| Diluted EPS | -0.26 | -0.22 ≈ | -0.26 | -0.27 | -0.26 | -0.28 ≈ | -0.31 | -0.27 |
| Operating cash flow | -8.6 m ≈ | -9.9 m | -9.1 m | -9.7 m ≈ | -9.1 m ≈ | -3.2 m | -15.1 m | -12.7 m ≈ |
| Capex | 223.0 k ≈ | 98.0 k | 319.0 k | 366.0 k ≈ | 73.0 k ≈ | 92.0 k | 394.0 k | -223.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 16.1 m | 23.2 m | 17.1 m | 22.5 m | 28.1 m | 33.6 m |
| Revenue YoY | unavailable | +44.5% | −26.3% | +31.4% | +24.6% | +19.7% |
| Net income | -37.1 m | -73.5 m | -60.8 m | -52.5 m | -46.9 m | -47.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -126.11 | -3.94 | -1.43 | -1.22 | -1.08 | -1.05 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -230.6% | -316.5% | -354.9% | -233.0% | -167.2% | -140.3% |
| Free cash flow | -31.7 m | -58.2 m | -65.3 m | -46.9 m | -45.5 m | -31.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 20.0 m USD
- Financial debt
- 18.9 m USD
- Net debt
- -1.1 m USD
- Equity
- 33.2 m USD
- Total assets
- 74.9 m USD
- Debt / equity
- 0.57x
- Current ratio
- 3.31x
- ROE
- -86.8%
- ROA
- -54.5%
- FCF margin
- -95.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 16.1 m | 23.2 m | 17.1 m | 22.5 m | 28.1 m | 33.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Research & development | 6.5 m | 9.8 m | 12.9 m | 12.8 m | 14.6 m | 13.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Operating income | -30.5 m | -47.2 m | -63.2 m | -56.6 m | -49.9 m | -47.4 m | SEC (XBRL)· 12 Mar 2026verified |
| Depreciation & amortisation | 1.5 m | 1.5 m | 2.8 m | 3.1 m | 3.4 m | 3.3 m | SEC (XBRL)· 12 Mar 2026verified |
| EBITDA | -29.0 m ≈ | -45.7 m ≈ | -60.4 m ≈ | -53.5 m ≈ | -46.6 m ≈ | -44.1 m ≈ | SEC (XBRL)· 12 Mar 2026derived |
| Interest expense | 3.4 m | 2.7 m | — | — | 40.0 k | 1.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Pre-tax income | -36.9 m | -73.4 m | -61.4 m | -52.4 m | -46.9 m | -47.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Income tax | 134.0 k | 91.0 k | -576.0 k | 31.0 k | 22.0 k | 40.0 k | SEC (XBRL)· 12 Mar 2026verified |
| Net income | -37.1 m | -73.5 m | -60.8 m | -52.5 m | -46.9 m | -47.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Diluted EPS | -126.11 | -3.94 | -1.43 | -1.22 | -1.08 | -1.05 | SEC (XBRL)· 12 Mar 2026verified |
| Weighted average diluted shares | 358.6 k | 19.8 m | 42.5 m | 43.0 m | 43.6 m | 44.7 m | SEC (XBRL)· 12 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 30.1 m | 178.4 m | 27.1 m | 24.3 m | 16.9 m | 20.0 m | SEC (XBRL)· 12 Mar 2026verified |
| Receivables | 5.0 m | 5.0 m | 5.4 m | 5.5 m | 7.5 m | 3.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Inventories | 9.0 m | 15.7 m | 21.2 m | 20.0 m | 20.2 m | 17.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Current assets | 62.2 m | 218.1 m | 138.6 m | 120.4 m | 80.9 m | 61.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Property, plant & equipment, net | 7.1 m | 11.3 m | 13.8 m | 12.8 m | 11.2 m | 9.0 m | SEC (XBRL)· 12 Mar 2026verified |
| Total assets | 70.0 m | 241.2 m | 190.7 m | 143.5 m | 98.2 m | 74.9 m | SEC (XBRL)· 12 Mar 2026verified |
| Accounts payable | 4.5 m | 3.9 m | 5.4 m | 2.0 m | 2.5 m | 4.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Long-term debt | 24.8 m | 0 | 0 | — | 0 | 18.9 m | SEC (XBRL)· 12 Mar 2026verified |
| Current liabilities | 15.5 m | 18.2 m | 19.1 m | 19.0 m | 17.6 m | 18.5 m | SEC (XBRL)· 12 Mar 2026verified |
| Total liabilities | 45.2 m | 20.2 m | 26.5 m | 25.5 m | 22.8 m | 41.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Equity | -127.0 m † | 221.0 m † | 164.2 m † | 118.0 m † | 75.4 m † | 33.2 m † | SEC (XBRL)· 12 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -31.0 m | -55.0 m | -58.5 m | -45.1 m | -44.2 m | -31.1 m | SEC (XBRL)· 12 Mar 2026verified |
| Capex | 690.0 k | 3.2 m | 6.7 m | 1.8 m | 1.4 m | 850.0 k | SEC (XBRL)· 12 Mar 2026verified |
| Free cash flow | -31.7 m ≈ | -58.2 m ≈ | -65.3 m ≈ | -46.9 m ≈ | -45.5 m ≈ | -31.9 m ≈ | SEC (XBRL)· 12 Mar 2026derived |
| Investing cash flow | -15.7 m | -13.3 m | -93.5 m | 42.2 m | 36.7 m | 14.3 m | SEC (XBRL)· 12 Mar 2026verified |
| Financing cash flow | 64.2 m | 216.7 m | 693.0 k | 149.0 k | 203.0 k | 19.8 m | SEC (XBRL)· 12 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 35.4% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
35% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -188.3% | 0 (vs peers) | 29% |
| Net margin · Quality | -145.6% | 16 (vs peers) | 18% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 25.2% | 100 (on a fixed band) | 24% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -21.2x | 0 (on a fixed band) | 18% |
| Current ratio · Balance sheet | 2.5x | 100 (on a fixed band) | 12% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality6/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Rapid Micro Biosystems, Inc. (RPID). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 33.6 m USD in 2025; YoY growth 19.7%; net margin -145.6%; ROE -141.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 25.2%
- Current ratio: 2.5x
What contradicts it
- ROIC: -188.3%
- Net margin: -145.6%
- Interest coverage: -21.2x
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Laboratory Analytical Instruments (SIC 3826) · same industry (4-digit SIC) · compared with 20 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AAgilent Technologies, Inc. | 49.9 bn | 34.9 | 21.0% | 19.5% | +6.7% | +15% / +39% |
| WATWaters Corporation | 45.9 bn | 116.6 | 1.9% | 3.6% | +7.0% | +16% / +67% |
| MTDMettler-Toledo International Inc. | 34.5 bn | 38.8 | — | 21.9% | +4.0% | +17% / +58% |
| ILMNIllumina, Inc. | 34.3 bn | 38.8 | 32.4% | 19.7% | −0.7% | +72% / +128% |
| RVTYRevvity, Inc | 17.8 bn | 76.0 | 3.2% | 8.2% | +3.7% | +53% / +79% |
| AVTRAvantor, Inc. | 10.6 bn | 31.5 | 5.9% | 5.1% | −3.4% | +33% / −26% |
| BRKRBruker Corporation | 9.7 bn | — | -3.4% | -2.0% | +2.1% | +31% / −2% |
| TXG10x Genomics, Inc. | 8.6 bn | — | -9.4% | -12.2% | +5.2% | +259% / +55% |
| PACBPacific Biosciences of California, Inc. | 792.6 m | — | -929.3% | -82.5% | +3.9% | +10% / −70% |
| CTKBCytek Biosciences, Inc. | 769.0 m | — | -23.2% | -39.1% | +0.5% | +4% / −15% |
| MASS908 Devices Inc. | 457.6 m | — | -25.2% | -57.0% | +17.7% | +74% / +39% |
| NAUTNautilus Biotechnology, Inc. | 291.7 m | — | -41.0% | — | unavailable | +2% / −17% |
| QTRXQuanterix Corporation | 143.8 m | — | -46.5% | -80.2% | +1.1% | −58% / −87% |
| SEERSeer, Inc. | 94.1 m | — | -26.4% | -478.0% | +17.0% | −11% / +6% |
| HBIOHarvard Bioscience, Inc. | 39.2 m | — | -89.9% | -11.9% | −8.1% | +13% / −80% |
| PRPOPrecipio, Inc. | 35.0 m | — | -9.0% | -4.5% | +29.8% | −20% / +187% |
| EYPTEyePoint, Inc. | 34.1 m | — | -148.7% | -10,994.7% | −27.5% | −97% / −94% |
| BNGOBionano Genomics, Inc. | 14.0 m | — | -83.6% | -106.6% | −7.4% | −36% / −99% |
| ASTCAstrotech Corporation | 9.1 m | — | -75.4% | -1,580.2% | −8.7% | +41% / −44% |
| BIOBio-Rad Laboratories, Inc. | — | 10.0 | 14.3% | 39.5% | +0.7% | +17% / +25% |
| RPIDRapid Micro Biosystems, Inc. | — | — | -141.6% | -145.6% | +19.7% | −75% / −38% |
1- and 3-year price returns: for RPID from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Rapid Micro Biosystems develops the Growth Direct platform, an automated system for microbial quality control in pharmaceutical manufacturing, used especially for biologics, cell and gene therapies. The company is pushing toward full automation of MQC testing, and its distribution agreement with MilliporeSigma and growing recurring revenue could support a steadier trajectory if system placements keep pace; 2025 revenue was 33.6 million USD, with a net loss of 47.1 million USD.
SWOT
Strengths
- Automated platform with proprietary consumables and an installed base across several countries that generates recurring revenue after validation.
- Reference customers in the pharmaceutical industry and in cell and gene therapies, which supports product credibility.
- Collaboration with a large global distributor, which could widen market access in certain regions.
Weaknesses
- Repeated net losses and a large accumulated deficit, with positive cash flow not yet achieved.
- Gross margin still low and not yet covering infrastructure costs, although it has improved in recent years.
- Revenue concentrated in a small number of large customers, which makes quarterly results volatile.
Opportunities
- Growth in biologics and cell and gene therapies, which carry high MQC testing intensity per batch.
- Expansion into multi-system and multi-site deployments at existing customers, which could raise recurring revenue.
- Reshoring of manufacturing to the U.S. and investment in new biomanufacturing capacity.
Threats
- Customers postponing capital investment during periods of economic uncertainty or high interest rates.
- Emergence of competing platforms, or continued adoption of manual methods by conservative customers.
- Dependence on financing conditions and on the release of credit tranches tied to operating metrics.
Risks
- Continuing losses and lack of profitabilityhigh
The company has not yet reached profitability and cannot guarantee that it will achieve positive cash flow. If revenue or margin does not grow enough, its capital needs could increase.
- Dependence on the success of the Growth Direct platformhigh
The entire business depends on adoption of the system, consumables and services. A failure to gain market acceptance would significantly affect results.
- Volatility of quarterly resultsmedium
Revenue and margin vary widely from quarter to quarter, depending on large system orders and validation timing. The company warns that results may not be indicative of future periods.
- Reliability of financial guidancemedium
Published guidance relies on system orders and delivery schedules that the company does not always control. Failure to meet guidance could affect its reputation and share price.
- Debt and financing conditionsmedium
Access to additional tranches of the loan facility depends on meeting revenue and margin metrics. If these are not met, liquidity could become a concern.
Investment thesis
What would need to be true (bull case)
- If consumables and recurring revenue keep growing faster than the total, the company could gradually reduce its reliance on system sales and move closer to positive cash flow.
- The collaboration with a global distributor and expansion into multi-system site deployments could accelerate placements and improve margins over the medium term.
- Growth in cell and gene therapies and reshoring to the U.S. could create sustained demand for automated testing.
What would break the thesis
- Repeated net losses show the business model has not yet reached balance, and if margins do not improve enough, the company could need additional financing.
- System sales are hard to forecast and may be deferred by customers during economic uncertainty, which could weigh on quarterly results.
- Reliance on a small number of large customers and on the release of conditional financing tranches could limit the company's flexibility.
What to watch
- Revenue and system placements against annual guidanceQ3 2026
- Gross margin reaching the mid-20% range in the second half of 2026next 10-K
- Release of the first additional tranche under the loan facilityQ1 2027
- Effects of the European MilliporeSigma event on the sales pipeline2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Rapid Micro Biosystems is a life sciences technology company providing automation solutions for the manufacturing and fast, safe release of healthcare products. Its flagship Growth Direct platform combines robotic handling, optical imaging and image analysis algorithms to automate microbial quality control testing, which has traditionally been manual and slow. The business model covers system sales, proprietary consumables, and validation and maintenance services that generate recurring revenue after installation, according to source 1.
The Growth Direct platform consists of the system itself, proprietary consumables, LIMS connection software, and support and validation services. The company says it reduces time to results by 50% or more compared with the traditional method, which makes it attractive to customers who want faster batch release. The offering is designed to absorb most of a facility's daily test volume, including in configurations of several systems per site.
The company has accumulated significant losses and is not yet profitable. Revenue grew in 2025 over the prior year, and moderate growth continued into the first half of 2026. The stated strategy aims at positive cash flow without additional financing, a goal the company ties to revenue growth and gross margin improvement, according to its SEC filings.
Segments
Growth Direct systems
Growth Direct system sales are capital sales, with revenue concentrated in a relatively small group of customers each year. The company had placed 190 systems by the end of 2025 and passed 200 placed systems in Q2 2026, according to source 3.
Consumables and recurring services
Proprietary consumables and service contracts generate recurring revenue after a system is validated at a customer site. This component grew faster than total revenue in the second quarter of 2026, which could reduce dependence on system sales if the trend holds.
MilliporeSigma collaboration
The February 2025 distribution agreement gives MilliporeSigma co-exclusive rights to sell in certain industrial quality control fields. The company keeps direct sales, and a supply agreement could help improve consumables margins.
Market context
The company estimates the system sales market at about 5.0 billion USD and the recurring consumables and services market at a similar value, based on an annual volume of about 350 million tests. These estimates come from the annual report and reflect management's assessment, not independent market data 1.
Demand is supported by tighter data integrity regulation, growth in biologics and cell and gene therapies, and the reshoring of pharmaceutical manufacturing to the U.S. Labor shortages and manufacturing efficiency pressures could speed automation adoption, but buying pace depends on customers' budget cycles.
Trends
- Reshoring of pharmaceutical manufacturing to the U.S.tailwind
The company believes that bringing drug manufacturing back to the U.S. could increase demand for efficient MQC testing. If investment in new capacity materializes, the number of units requiring systems could grow.
- Focus on data integritytailwind
Regulators are paying closer attention to data integrity in quality control labs, which favors digitized systems with audit trails. The Growth Direct platform is presented as an answer to this requirement.
- Budget cycles and deferred capital spendingheadwind
System sales are capital investments, and economic uncertainty, inflation and high interest rates could lead customers to postpone decisions. The company explicitly flags these risks in its SEC filings.
- Tariffs and cost inflationmixed
Tariffs and inflation raise labor, materials and freight costs, which could weigh on gross margin. The company has nonetheless reported margin improvement, though its path remains non-linear.
Competitive position
The supplied sources do not detail direct competitors. The company presents itself as the first to solve the barriers to MQC automation, but the market also includes traditional manual methods and other automated platforms, mentioned only generically in the risk factors.
The stated advantage lies in the combination of full automation, proprietary consumables and validation, which makes switching to another supplier costly for a customer. However, without independent market share analysis, the relative position is hard to assess.
- Traditional manual colony counting methods
The main alternative is the manual growth-based plate method with visual inspection, which the company considers slow and error-prone.
- Other automated MQC testing platforms
Risk factors mention the existence of other automated MQC testing platforms, without identifying them in the supplied sources.
- Distribution partner MilliporeSigma
A distribution partner can also become a competitor in some channels, since it holds co-exclusive selling rights.
- Generic consumables suppliers and in-house laboratories
Customers may keep using generic consumables and in-house laboratories, which limits adoption of the proprietary platform.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report07 Aug 2026
- Current report07 Aug 2026Results of operations · Financial statements and exhibits
- Current report28 May 2026Shareholder vote
- Current report19 May 2026Material agreement · Financial statements and exhibits
- Quarterly report15 May 2026
- Current report13 May 2026Results of operations · Financial statements and exhibits
- Proxy statement08 Apr 2026
- Current report27 Mar 2026Departure or appointment of officers · Financial statements and exhibits
- Annual report12 Mar 2026
- Current report12 Mar 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Rapid Micro Biosystems, Inc. · 12 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Rapid Micro Biosystems, Inc. · 07 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Rapid Micro Biosystems, Inc. · 07 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.